SELECT SECTOR

PHARMA & LIFE SCIENCES: LATEST INTERVIEWS MORE INTERVIEWS

Mike Radomsky
PRESIDENT, CMC PHARMACEUTICALS
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
United States
Pharma & Life Sciences
Andrea Confetti and Roberto Fa...
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADE...
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
United States
Pharma & Life Sciences
Donna LaVoie
FOUNDER AND CEO, LAVOIEHEALTHSCIENCE
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
United States
Pharma & Life Sciences
Debbie Hart
PRESIDENT AND CEO, BIONJ
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
United States
Pharma & Life Sciences

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Mexico Chemicals 2025 CW Release

Mexico's chemical industry faces challenges in securing a reliable feedstock supply and maintaining global competitiveness. A shift towards sustainable energy and local production could provide long-term growth opportunities, and some sectors are booming, including Mexico's dynamic chemical distribution market.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL